Related to What Does It Take to Swing the IPO Window Open for Biotechs?

• SBIR Thinks Smaller
  New rules taking effect on January 28 aim to draw investor-owned smaller biopharmas to the federal grant program and STTR, its companion.
  
• No Passage to India
  Private investment dearth clouds the future of the subcontinent’s fast-growing biopharma industry.
  
• Top 10 VC & Biopharma Equity Deals of 2012
  Which companies raised the most funds last year?
  
• Top 20 Best-Selling Drugs of 2012
  Which drugs were the biggest hits last year?
  
• Funding Squeeze Traps Young Researchers
  Postdocs look beyond NIH funding as, despite policy changes, the percentage and age of first-time grant winners stay steady.
  
• Top 20 Biopharma R&D Spenders
  Which companies have the deepest pockets for research and development?
  
• 20 Grants for Young Researchers
  Looking for funding? Here are some places to start.
  
• Is Brain Mapping Ready for Big Science?
  The BAM project will be an expensive undertaking. Will it be worth the cost?
  
• Top 22 R&D Spenders among Tool and Technologies Companies
  Find out how much money goes into developing the instruments you use for research.
  
• Top 20 Best-Selling Drugs Approved and Launched During 2012
  What new medicines are shaking things up?
  
• CEO Perks
  These 18 top dogs have got it good.
  
• Two Roads to Wowing the Crowd
  Poliwogg eyes biopharma startups seeking millions; Microryza connects donors to researchers needing thousands.
  
• GEN Congressional Hall of Fame
  Biomedical research has friends in high places. Meet them.
  
• Biotech Companies Face the Key Question—Deal or No Deal?
  Advice: Set aside dreams of becoming the next Amgen or Genentech; instead know when to partner, take the money, and run.
  
• Mergers and Acquisitions—The New IPO
  Tips for a strong communication strategy that will lure shareholders and investors over to your side.
  
• BIO Investor: IPOs, Financing, and the Need for New Flu Treatments
  Presenters believe that M&A will shift to deals between biotech firms and that new technologies will improve vaccine production.
  
• How Biotech Unions Could Save Companies and Revitalize Pipelines
  Impetus for such mergers comes from the drying up of venture funds and pharma consolidation.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• Buyout Options Gaining a Foothold in Deals Means that More than the Price Is Right
  Buyout rights are attractive to smaller firms as they offer up-front payments and a longer-term path to liquidity.
  
• M&A Likely to Continue Growing Along with Deal Premiums and Multiples
  Slow comeback of IPO market will keep companies looking for opportunities to be acquired.